Q1 EPS Estimates for Aktis Oncology Boosted by HC Wainwright

Chronological Source Flow
Back

AI Fusion Summary

HC Wainwright raised Aktis Oncology Q1 2026 EPS to $0.36 from $0.64, keeping a Buy rating and $33 target. It lifted Knightscope FY2026 EPS to $2.48 from $2.78, with a $12 target. Nanobiotix FY2026 EPS was cut to $1.05 from $1.06.
#HC_WAINRIGHT #AKTS #KSCP #NBTX #BUY_RATING #EPS_ESTIMATE #TARGET_PRICE
03/04 08:08 defenseworld.net
3 Πηγές

Q1 EPS Estimates for Aktis Oncology Boosted by HC Wainwright

Aktis OncologyHC WainwrightEPS estimateBuy rating$33 price objectiveQ1 2026
03/04 08:24 defenseworld.net

Knightscope FY2026 EPS Estimate Boosted by HC Wainwright

ANALYST ARTICLES - ESTIMATESEARTHQUAKEPOLITICSCOMPANIES
03/04 08:54 defenseworld.net

FY2026 EPS Estimates for Nanobiotix Cut by HC Wainwright

COMPANIESPOLITICSANALYST ARTICLES - ESTIMATESEARTHQUAKE
Comments
Loading...
0